Successes and challenges of PARP inhibitors in cancer therapy

Frontiers in Oncology

Volumn 5, Issue OCT, 2015, Pages

  Ricks, Tiffany K ^a   Chiu, Haw Jyh ^a   Ison, Gwynn ^a   Kim, Geoffrey ^a   McKee, Amy E ^a   Kluetz, Paul ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

BRCA1; BRCA2; Cancer; Drug resistance; Homologous recombination; PARP inhibitor

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; TALAZOPARIB; VELIPARIB;

CANCER THERAPY; CYTOTOXICITY; DNA DAMAGE; DNA END JOINING REPAIR; DNA REPAIR; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DELETION; HUMAN; HUMAN CELL; IC50; IC90; NOTE; OVARY CANCER; PROTEIN DNA BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; WESTERN BLOTTING;

EID: 84947078204     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00222     Document Type: Note

References (43)

1. Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol (2012) 13:411-24. doi: 10.1038/nrm3376
2. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol (2006) 7:517-28. doi:10.1038/nrm1963
3. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 434:913-7. doi:10.1038/nature03443
4. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 434:917-21. doi:10.1038/nature03445
5. Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T, et al. FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res (2015) 21:4257-61. doi:10.1158/1078-0432.CCR-15-0887
6. Curtin NJ, Szabo C. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Aspects Med (2013) 34:1217-56. doi:10.1016/j.mam.2013.01.006
7. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer (2010) 10:293-301. doi:10.1038/nrc2812
8. Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res (2013) 19:5003-15. doi:10.1158/1078-0432.CCR-13-1391
9. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res (2008) 14:7917-23. doi:10.1158/1078-0432.CCR-08-1223
10. Durkacz BW, Omidiji O, Gray DA, Shall S. (ADP-ribose)n participates in DNA excision repair. Nature (1980) 283:593-6. doi:10.1038/283593a0
11. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res (2006) 66:8109-15. doi:10.1158/0008-5472.CAN-06-0140
12. Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A (2011) 108:3406-11. doi:10.1073/pnas.1013715108
13. De Lorenzo SB, Patel AG, Hurley RM, Kaufmann SH. The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells. Front Oncol (2013) 3:228. doi:10.3389/fonc.2013.00228
14. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol (2011) 5:387-93. doi:10.1016/j.molonc.2011.07.001
15. Galande S, Kohwi-Shigematsu T. Poly(ADP-ribose) polymerase and Ku autoantigen form a complex and synergistically bind to matrix attachment sequences. J Biol Chem (1999) 274:20521-8. doi:10.1074/jbc.274.29.20521
16. Li B, Navarro S, Kasahara N, Comai L. Identification and biochemical characterization of a Werner's syndrome protein complex with Ku70/80 and poly(ADP-ribose) polymerase-1. J Biol Chem (2004) 279:13659-67. doi:10.1074/jbc.M311606200
17. Pleschke JM, Kleczkowska HE, Strohm M, Althaus FR. Poly(ADP-ribose) binds to specific domains in DNA damage checkpoint proteins. J Biol Chem (2000) 275:40974-80. doi:10.1074/jbc.M006520200
18. Wang M, Wu W, Wu W, Rosidi B, Zhang L, Wang H, et al. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res (2006) 34:6170-82. doi:10.1093/nar/gkl840
19. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP Inhibitors. Cancer Res (2012) 72:5588-99. doi:10.1158/0008-5472.CAN-12-2753
20. Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther (2014) 13:433-43. doi:10.1158/1535-7163.MCT-13-0803
21. Strom CE, Johansson F, Uhlen M, Szigyarto CA, Erixon K, Helleday T. Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res (2011) 39:3166-75. doi:10.1093/nar/gkq1241
22. Hopkins TA, Shi Y, Rodriguez LE, Solomon LR, Donawho CK, Digiammarino EL, et al. Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP Inhibitors. Mol Cancer Res (2015). doi:10.1158/1541-7786.MCR-15-0191-T
23. Kinders RJ, Hollingshead M, Khin S, Rubinstein L, Tomaszewski JE, Doroshow JH, et al. Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts. Clin Cancer Res (2008) 14:6877-85. doi:10.1158/1078-0432.CCR-08-0214
24. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol (2009) 27:2705-11. doi:10.1200/JCO.2008.19.7681
25. Ji J, Kinders RJ, Zhang Y, Rubinstein L, Kummar S, Parchment RE, et al. Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells. PLoS One (2011) 6:e26152. doi:10.1371/journal.pone.0026152
26. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 376:245-51. doi:10.1016/S0140-6736(10)60893-8
27. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (2010) 376:235-44. doi:10.1016/S0140-6736(10)60892-6
28. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 361:123-34. doi:10.1056/NEJMoa0900212
29. Bouwman P, Jonkers J. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? Clin Cancer Res (2014) 20:540-7. doi:10.1158/1078-0432.CCR-13-0225
30. Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol (2008) 8:363-9. doi:10.1016/j.coph.2008.06.016
31. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 451:1111-5. doi:10.1038/nature06548
32. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 451:1116-20. doi:10.1038/nature06633
33. Barber LJ, Sandhu S, Chen L, Campbell J, Kozarewa I, Fenwick K, et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol (2013) 229:422-9. doi:10.1002/path.4140
34. Fojo T, Bates S. Mechanisms of resistance to PARP inhibitors-three and counting. Cancer Discov (2013) 3:20-3. doi:10.1158/2159-8290.CD-12-0514
35. Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov (2013) 3:68-81. doi:10.1158/2159-8290.CD-12-0049
36. Lowndes NF, Toh GW. DNA repair: the importance of phosphorylating histone H2AX. Curr Biol (2005) 15:R99-102. doi:10.1016/j.cub.2005.01.029
37. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem (1998) 273:5858-68. doi:10.1074/jbc.273.10.5858
38. Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, et al. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res (2015) 21:819-32. doi:10.1158/1078-0432.CCR-14-2572
39. D'Andrea AD. Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med (2010) 362:1909-19. doi:10.1056/NEJMra0809889
40. Meyer S, Tischkowitz M, Chandler K, Gillespie A, Birch JM, Evans DG. Fanconi anaemia, BRCA2 mutations and childhood cancer: a developmental perspective from clinical and epidemiological observations with implications for genetic counselling. J Med Genet (2014) 51:71-5. doi:10.1136/jmedgenet-2013-101642
41. McNeish IA, Oza AM, Coleman RL, Scott CL, Konecny GE, Tinker A, et al. Results of ARIEL2: a Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis. ASCO Meeting Abstracts (2015) 33:5508.
42. Watkins JA, Irshad S, Grigoriadis A, Tutt AN. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res (2014) 16:211. doi:10.1186/bcr3670
43. Michels J, Vitale I, Saparbaev M, Castedo M, Kroemer G. Predictive biomarkers for cancer therapy with PARP inhibitors. Oncogene (2014) 33:3894-907. doi:10.1038/onc.2013.352